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 Abstract 
 
By assessing the amount and geographic distribution of genetic variation in moose we 
can better understand how microevolutionary processes and landscape features have 
influenced that variation. How the distribution of moose changes in the future will be 
partially dictated by the amount and content of genetic variation moose populations 
possess. Therefore, it will be useful to acquire more moose population genetic data and to 
study declining populations. My thesis had two primary objectives: (1) to compare the 
efficacy of DNA extraction from different biological samples and (2) to genotype a 
subset of Minnesota moose at a locus known to be associated with chronic wasting 
disease in other cervid populations. DNA for genetic analyses was extracted from blood, 
tissue, and pellets. Extracted DNA from all source types was sufficient for genotyping 
using 15 microsatellites and Sanger sequencing. However, DNA extracted from pellets 
was of both lower quality and quantity than DNA extracted from blood and tissue. 
Minnesota moose contain polymorphisms that have been correlated with increased 
susceptibility to chronic wasting disease in cervids in other areas. These results provide 
valuable comparisons of efficiency and effectiveness of DNA extraction protocols for 
tissue, blood, and fecal pellets as well as baseline population genetic data that can be used 
to detect future genetic changes in these populations.  
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Chapter 1 A Methodological Comparison between DNA 
Source Types in Moose 
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Introduction 
 
An important advance in population and conservation genetics has been the 
ability to obtain DNA from multiple biological source types (Waits et al. 2005). The 
DNA source types used most often in population genetic research on ungulates are tissue 
and blood. Samples are obtained from dead animals from hunter harvest or vehicle 
collisions, or from live animals captured for research purposes (Coulon et al. 2004; 
Kangas et al. 2013; Wilson et al. 2015). Blood and tissue samples collected during GPS 
collar captures have been used as DNA sources in several cervid population genetic 
studies (Kangas et al. 2013; Wilson et al. 2015; Finnegan et al. 2011). 
More recently, noninvasively collected fecal pellets have been used as an 
alternative source of DNA. Fecal pellets, referred to hereafter as pellets, can be collected 
from multiple individuals over a broad geographic region and are relatively easy to 
collect, particularly if fieldwork is conducted in winter months when fresh pellets are 
visible on snow. Pellets are an especially attractive DNA source in areas where 
noninvasive sampling may be desirable, such as parks.  
It is also beneficial to use DNA collected noninvasively for rare, elusive, or 
otherwise difficult to study species. For example, DNA from pellets has been used to 
estimate population size in roe deer (Capreolus capreolus) (Ebert et al. 2012) and Sitka 
black-tailed deer (Odocoileus hemionus sitkensis) (Brinkman et al. 2011), two species 
that live in densely vegetated, concealing habitats that are otherwise hard to survey. 
Population size, survival rate, and rate of population size change have been estimated for 
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a protected subspecies of woodland caribou in Canada using DNA from noninvasively 
collected pellets (Hettinga et al. 2012). 
Non-invasive genetic research based on DNA extracted from pellets has been 
done on several ungulate species, including mountain goat (Oreamnos americanus) 
(Poole et al. 2011), caribou (Rangifer tarandus caribou) (Hettinga et al. 2012), Sitka 
black-tailed deer (Brinkman et al. 2011; Brinkman et al. 2010a; Brinkman et al. 2010b), 
roe deer (Ebert et al. 2012), and red deer (Cervus elaphus) (Valière et al. 2007). 
The quality of DNA extracted from fecal pellets is a potential issue. Higher 
quantity and quality DNA is obtained from tissue and blood than from feces (Ball et al. 
2007; Waits & Paetkau, 2005). This is because DNA from feces is more degraded and 
more likely to be contaminated by other sources. The rate of DNA degradation is affected 
by the amount of time since deposition and environmental conditions (Brinkman et al. 
2010b; Kreader, 1996; Piggott, 2004). High air temperature, rainfall, bacteria and fungi, 
and exposure to UV radiation increase DNA degradation rate (Brinkman et al. 2010b; 
Buś & Allen, 2014; Piggott, 2004). 
DNA extracted from feces is further affected by the organism’s diet. Herbivore 
pellets contain tannins and other substances from the vegetation they consume, which 
increases the number of PCR inhibitors in the extracted DNA (Kreader, 1996). Carnivore 
scat includes prey DNA, which may inflate DNA concentration measurements, but will 
not further affect results if genetic markers used are species-specific. In addition to 
inherent factors involving the sample itself, proper collection and lab techniques, 
including sample collection, storage methods, and specified extraction protocols, are 
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necessary to ensure quality results from all DNA source types (Beja-Pereira et al. 2009; 
Buś & Allen, 2014; Waits & Paetkau, 2005). 
DNA quantity and quality are important because they directly affect PCR 
amplification, genotyping success, and error rates (Ball et al. 2007; Brinkman et al. 2010; 
Mckelvey & Schwartz, 2004; Taberlet et al. 1996; Waits & Paetkau, 2005). As DNA 
degrades, nucleic acid residues undergo chemical changes and strands become 
fragmented (Buś & Allen, 2014). DNA fragmentation results in lower PCR amplification 
success and increased genotyping errors (Taberlet et al. 1999). The most common PCR 
amplification errors using degraded DNA include false alleles, allelic dropout, and failure 
of DNA to amplify due to absence of usable DNA. 
Genetic techniques have been tested using DNA from various source types for 
several species (Ball et al. 2007; Beja-Pereira et al. 2009; Brinkman et al. 2011; Ebert et 
al. 2012; Kreader, 1996; Paetkau, 2003; Piggott, 2004; Poole et al. 2011; Waits & 
Paetkau, 2005), but there are few direct comparisons between source types for ungulates 
(Valière et al. 2007; Wehausen et al. 2004), and none for moose. All published moose 
population genetic research to date has used DNA from blood, tissue, or a combination of 
the two sources. Therefore, the aim of this study is to provide a comparison of DNA 
extracted from moose tissue, blood, and fecal pellets. Source type affects the time and 
resources required for population genetic studies, therefore, it would be useful to know 
relative extraction and genotyping success from different DNA sources. Using moose 
DNA extracted from tissue, blood, and pellets, we measured average DNA yield and 
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compared PCR amplification and genotyping success rates, as well as identified ways in 
which certain steps can be improved. 
 
Methods 
 
We compared DNA from biological sources collected in two study areas: northern 
Minnesota (MN) and the northern range of Yellowstone National Park (YNP) (Fig 1.1).  
 
Study areas 
Minnesota 
The study area includes northern Minnesota, transitioning from prairie in the west 
to mixed conifer-deciduous forests, bog, and swamp in the east. Northwestern (NW) MN 
is relatively flat and dominated by tallgrass prairie and farmland. Northeastern (NE) MN 
is characterized by conifer-deciduous forests, and conifer bogs and swamps. Vegetation 
in the NE consists of white pine (Pinus strobus), red pine (P. resinosa), quaking aspen 
(Populus tremuloides), paper birch (Betula papyrifera), white spruce (Picea glauca), 
balsam fir (Abies balsamea), and white cedar (Thuja occidentalis). Numerous small 
lakes, peatlands, and wet forest are also present throughout much of the NE portion of the 
state. The north-central region is a transition zone between the semi-arid prairie in the 
NW and relatively humid mixed conifer-deciduous forest in the NE. 
Yellowstone National Park 
The study area includes the portion of the Northern Yellowstone Elk Winter 
Range (Houston 1982) located within YNP as well as some creek drainages located 
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outside the park. Vegetation consists primarily of sage steppe and grassland at low 
elevation (<2,000 m), and coniferous forests at high elevation (3,000 m). The most 
common conifers are lodgepole pine (Pinus contorta), Engelmann spruce (Picea 
engelmannii), sub-alpine fir (Abies lasiocarpa), Douglas fir (Pseudotsuga menziesii), and 
whitebark pine (Pinus albicaulis Engelm.). Willow (Salix spp.) is present in drainages 
and other wet areas.  
 
Samples 
Minnesota 
Blood samples were collected by the Minnesota Department of Natural Resources 
(MNDNR) and stored on Whatman FTA® Classic Cards (Whatman International Ltd., 
Maidstone, UK), hereafter termed blood (Fig. 1.2). The blood samples were from hunter 
harvested (n=116), GPS collared (n=132), and sick (n=6) moose from 2011-2013. 
Samples for hunter harvested moose were not available in 2013 after the cancellation of 
the moose hunt (DelGiudice, 2013). Frozen liver tissue (n=31) samples from sick moose 
were collected from 2009-2012 throughout northern MN (Fig. 1.2). Moose health was 
determined by MNDNR based on a range of observations, such as non-normal behavior 
associated with neurological impairment, emaciation, and inability to stand upright. Sick 
moose were either found dead or were euthanized. Sex for blood and tissue samples from 
Minnesota moose was determined via direct observation of the animal by MNDNR or 
other wildlife researchers. Samples are from males (n=148), females (n=108), and 
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individuals of unknown sex (n=29).  FTA cards were stored at room temperature and 
frozen tissue was stored in -20°C freezers until analysis. 
Yellowstone National Park 
Pellet samples (n=489) were collected primarily along drainages in YNP (Fig. 
1.3). Sampling was conducted during winter months when snow was present on the 
ground. A minimum of five pellets from each deposition pile were collected for each 
sampled moose. Pellets were stored in Whirl-Pak® or Ziploc freezer bags. Tissue 
samples (n=2) were opportunistically collected from dead animals, frozen, and stored in 
Whirl-Pak® bags. Pellets and tissue collected in YNP were kept frozen and sent to the 
University of Minnesota-Duluth for analysis. Date and time of sample collection, 
location, and estimated age of sample was provided for most samples. Sex was 
determined directly, by collecting pellet samples from an observed animal or indirectly, 
by using physiological and behavioral clues, such as size of snow bed, presence of a calf, 
or tree rubbing. The age of pellet samples at collection was estimated based on direct 
observation of the moose, and sometimes of the pellet deposition itself, or by using 
evidence from the pellets, moose tracks, or snow cover if the moose was not directly 
observed. Frozen tissue and pellets were stored in -20°C freezers until analysis. 
 
Extraction 
Blood 
Whole genomic DNA was extracted from one drop of dried blood for each sample 
(n=251), using Fermentas/Thermo Scientific GeneJET Whole Blood Genomic DNA 
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Purification Mini Kit (Thermo Fisher Scientific Inc. Pittsburgh, PA) according to the 
manufacturer’s protocol (Supplementary materials). Each blood drop was taken from 
individual FTA cards using a 4 mm hand punch. Blood drops were categorized as small, 
medium, and large with diameters averaging approximately 7.4 mm, 9.8 mm, and 11.8 
mm, respectively. Extractions followed kit protocol, with one modification to improve 
final DNA yield, particularly for small blood drops. Small blood drops were eluted twice 
with 100 µl of Elution Buffer, the same 100 µl of Elution Buffer pipetted back into the 
spin column after being centrifuged, resulting in a final volume of 100 µl. Medium and 
large blood drops were eluted twice as well, but with new Elution Buffer for the second 
elution step, resulting in a final volume of 200 µl. 
Tissue 
DNA was extracted from 0.02 grams of frozen tissue (n=33) using Thermo 
Scientific GeneJET Genomic DNA Purification kit (Thermo Fisher Scientific Inc. 
Pittsburgh, PA) and the manufacturer’s protocol with modifications to improve final 
DNA yield and purity, including: (1) overnight incubation with Digestion Solution and 
Proteinase K instead of the manufacturer’s recommended 3-4 hours, (2) a minute added 
to each of the highest speed centrifugation times, (3) a minute added to the elution buffer 
incubation time, and (4) a second elution step, resulting in a final elution volume of 400 
µl (Supplementary Material). 
Pellets 
Three DNA extraction kits, QIAamp DNA Stool Mini Kit (Qiagen Inc. Valencia, 
CA), Thermo Scientific GeneJET Genomic DNA Purification Kit (Thermo Fisher 
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Scientific Inc. Pittsburgh, PA), and PowerFecal DNA Isolation Kit (MO BIO 
Laboratories, Inc. Carlsbad, CA), were tested during a pilot study using 30 pellet 
samples. Qiagen’s stool extraction kit produced sufficient DNA yield and PCR success, 
using our laboratory techniques (described below), and was chosen for large scale DNA 
extractions for pellet samples. DNA was extracted from pellets (n=489) using two Qiagen 
DNA extraction kits because the manufacturer discontinued the first kit we used mid-way 
through our study. The first method involved extracting DNA from one whole fecal pellet 
(n=301) using QIAamp DNA Stool Mini Kit (Qiagen Inc. Valencia, CA) and a modified 
protocol (Supplementary material). The protocol was designed to isolate DNA from 
intestinal cells sloughed off onto the surface of pellets (Estes-Zumpf et al. 2014). Inner 
pellet material can contain PCR inhibitors that lead to increased variability in PCR 
amplification and genotyping success rates (Flagstad et al. 1999; Wehausen et al. 2004). 
To exclude this material from the extraction process each pellet was submerged in stool 
lysis buffer, Buffer ASL, from the QIAamp DNA Stool Mini Kit, and agitated to rinse 
cells off the outer surface instead of vortexing, which can break up the pellet exposing the 
inner material.  
For the second method of extracting DNA from pellets (n=188) we used QIAamp 
Fast DNA Stool Mini Kit (Qiagen Inc. Valencia, CA) and the manufacturer’s protocol 
with several modifications to improve final DNA yield and purity, including: (1) 
centrifuging after step 2 to reduce bubbles caused by vortexing and (2) reducing 
centrifuge rates during step 14 to 6,000 x g instead of the manufacturer’s recommended 
20,000 x g (Supplementary material). This protocol required that a portion of the pellet, 
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instead of a whole pellet, be used. We used a razor to slice thin layers from the outer 
pellet material that contained the sloughed off cells. For both methods, pellets were kept 
frozen as long as possible, to prevent thaw and subsequent break up of pellets. We did not 
use pellets that were frozen together or pellets with ice or snow on them. 
 
Sex determination 
Sex was determined for each sample using SE47/SE48 primer pairs (Brinkman & 
Hundertmark, 2009). This primer pair produces a single band for females and a double 
band for males by PCR amplifying X- and Y-specific alleles of the amelogenin gene. 
This method has been previously used on moose and other cervid species (Brinkman & 
Hundertmark, 2009).  
PCR amplification was attempted for each sample using DNA diluted 1:1 with 1X 
TE Buffer. DNA that successfully amplified required no further testing for sex. If PCR 
amplification was unsuccessful, PCR was attempted a second time, again using DNA 
diluted 1:1. If PCR failed after the second attempt, PCR was attempted a final time, using 
undiluted DNA. PCR products for sex identification were visualized using gel 
electrophoresis on 1.5% agarose gels stained with 10 mg/mL of ethidium bromide.  
 
Genotyping 
DNA extracted from blood (n=248) and pellets (n=269) was genotyped using one 
sex-linked and 15 autosomal microsatellites previously used for moose (Table 1.1). Each 
microsatellite primer pair was tested to determine optimal PCR conditions (Table 1.1). 
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All autosomal forward primers contain an M13 (-21) tail on the 5’ end (Schuelke, 2000), 
and PCR products were labeled by incorporating a universal fluorescently-labeled M13 (-
21) primer (FAM, PET, or VIC) during PCR. For DNA extracted from blood sources, all 
microsatellites were amplified in MultiGene Optimax Gradient Thermal Cycler TC9610 
with a total volume of 13 µl containing sterile water, GoTaq DNA Polymerase and 1x 
GoTaq buffer (Promega Corporation, Madison, WI, USA), 2 mM MgCl2, 0.2 mM 
dNTPs, 0.08 µM forward primer, 0.8 µM reverse primer, 0.8 µM labeled primer, 1% 
bovine serum albumin (BSA), and 1 µl/reaction DNA. DNA used in PCR was either 
undiluted or diluted 1:1, based on what concentration was successful for sex 
determination. BSA was added to all PCR to bind potential inhibitors and improve 
amplification specificity (Kreader, 1996). The addition of BSA to PCR was initially 
implemented to increase amplification success using DNA extracted from pellets. It was 
added to PCR using DNA extracted from blood and tissue for consistency, and to 
potentially increase PCR amplification success for DNA from each source type.  
DNA extracted from pellet sources was amplified using the same set of 
microsatellite loci; however, an additional step was taken for PCR using this DNA due to 
low PCR amplification success rates determined in a pilot study. For DNA extracted from 
pellets, microsatellite loci were amplified using either single step or pre-amplification 
PCR methods (Table 1.1). Pre-amplification is a two-step PCR method designed to 
increase the amount of DNA template for amplification and reduce genotyping error 
(Piggott et al. 2004). The success of the pre-amplification method has been questioned 
(Hedmark & Ellegren, 2006; De Barba & Waits, 2010); therefore, we conducted a pilot 
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study to test this method using DNA extracted from pellets amplified using our 
microsatellites. The pre-amplification method was used only on loci for which it 
increased PCR amplification success and subsequent genotyping success. PCR mixtures 
for both methods are shown in Table 1.2. 
 
Analyses 
PCR products were analyzed at the University of Minnesota Biomedical 
Genomics Center using an ABI 3730xl capillary genetic analyzer. Genotypes were 
assigned using GeneMarker (v.2.6.0, Softgenetics LLC, State College, PA) to score 
alleles for each locus. Failed or ambiguous allele scores were re-amplified and genotyped 
to reduce scoring errors and missing data.   
DNA quantification 
DNA extracted from blood, tissue, and pellets was quantified using a NanoDrop 
ND-1000 spectrophotometer to measure DNA concentration for each sample. Using 
DNA concentration and total extraction volume, we determined total DNA yield from 
each extraction for comparison. We also compared the two protocols for DNA extraction 
from pellets to determine which method resulted in higher DNA yield. DNA yield was 
compared between blood, tissue, and pellet samples using ANOVA, followed by pairwise 
comparisons between each sample type using two-sample t-tests.  
Sex determination 
Sex determination success rates were compared between DNA extracted from 
blood, tissue, and pellet samples using Fisher’s exact test. The accuracy of sex 
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determination using genetic methods was determined by comparing genetically 
determined sex with recorded sex from direct field observations using DNA from blood, 
tissue, and pellet samples. Additionally, we compared genetically determined sex with 
recorded sex from indirect field observations using DNA from pellet samples.  
PCR and genotyping success rates 
PCR amplification of autosomal microsatellites and genotyping success rates 
were calculated as a measure of DNA quality. Genotyping success rate is the proportion 
of microsatellites at which we were able to obtain genotypes for a given sample. To 
obtain overall genotyping success, PCR and allele scoring was attempted a second time 
for DNA samples if the first attempt failed. The genotyping success rate allows us to 
compare overall success using DNA from several DNA source types, however, it does 
not reflect the amount of effort and resources required to obtain that success. Therefore, 
we also calculated autosomal PCR success rate, the proportion of PCR amplification 
attempts that were successful, as a measure of effort required. PCR attempts were 
classified as successful if they produced viable product that was able to be used to 
genotype individuals. Autosomal PCR success rates using DNA extracted from blood and 
pellets were compared using chi-square test for independence. Genotyping success rates 
were compared using DNA extracted from blood and pellet samples using two-sample t-
tests. 
Genotyping error 
A concern when working with lower quality and quantity DNA, primarily from 
fecal samples, is the increased risk of genotyping errors such as allelic dropout or false 
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alleles. To estimate genotyping accuracy, we repeated PCR and allele scoring for at least 
12 and 24 individuals at each microsatellite locus using previously extracted DNA from 
blood and pellets, respectively. Because original repetitions using DNA extracted from 
pellet samples did not produce a usable amplicon, 95 additional DNA samples were 
repeated at 6 microsatellite loci. Genotyping error was calculated using these duplicated 
allele scores.  
Predictors of downstream success 
 To identify ways to improve efficiency and success rates, we tested DNA yield 
and sex determination success on downstream success. We used linear regression and 
two-sample t-tests to determine whether higher DNA yield or PCR amplification success 
of SE47/SE48, respectively, resulted in greater genotyping success. If DNA yield or PCR 
amplification success leads to greater genotyping success, these methods can be used to 
identify poor quality samples for removal, reducing the amount of time and effort spent 
on those samples. 
Effect of pellet age 
Since numerous environmental factors degrade DNA, we investigated whether the 
time between deposition and collection affects DNA quality and quantity. Time since 
deposition was estimated for pellet samples based on observations made in the field 
during collection, including visual pellet characteristics, moose tracks, and snowfall. 
Using these data, DNA from pellets was separated into three age classes: <24 hours 
(n=84), 24-48 hours (n=65), and >48 hours (n=109) since deposition. 
We compared DNA yield between age classes using ANOVA to determine if time 
since deposition affected the amount of DNA obtained from pellets. We compared sex-
  15 
    50 
linked and autosomal PCR amplification success between age classes using Fisher’s 
exact and Chi-squared tests, respectively. Finally, we used two-sample t-tests to 
determine if age since deposition affected overall genotyping success. Because of 
potential difficulty in differentiating pellets deposited <24 hours and 24-48 hours since 
deposition, we compared PCR amplification and genotyping success rates between DNA 
from pellets collected <48 hours and >48 hours after deposition. 
 
Results 
 
DNA yield 
We compared yield for DNA extracted from blood (n=251), tissue (n=33), and 
pellet (n=489) samples. Extracted DNA yield for blood, tissue, and pellet samples was 
sufficient for genotyping, however, tissue samples produced the highest average DNA 
yield, and pellets produced the lowest average DNA yield (Fig. 1.4). DNA extractions 
using sliced pellets had higher average DNA yield than extractions using whole pellets 
(Fig. 1.4).  
 
Sex determination 
We determined sex with primer pair SE47/SE48 using DNA extracted from all 
three sample sources. Sex determination was successful for 100% of blood samples 
(n=254), 91% of tissue samples (n=33), and 83% of pellet samples (n=460) (Table 1.3). 
We calculated the accuracy of sex determination using these methods by comparing 
results determined genetically to those in the field when the individual was observed 
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directly. Genetic and field sex determination was consistent for 219 of 225 blood samples 
(0.97), 24 of 25 tissue samples (0.96), and 64 of 67 pellet samples (0.96) when analyzed 
separately. When sex was determined in the field by indirect observation of moose in 
YNP, genetic and field determined sex were consistent for 74 of 100 pellet samples 
(0.74). Genetic sex determination was inconsistent with indirect field determined sex in 
similar proportions in samples identified as male (0.42) and female (0.58) in the field. 
 
Genotyping and PCR success rates 
We genotyped 517 total moose samples using DNA from blood (n=248) and 
pellets (n=269) at 15 autosomal microsatellite markers. Average PCR amplification 
success rate was higher for blood (0.81) than pellets (0.63) (Table 1.4). Similarly, average 
genotyping success rate, the percent of microsatellites that we were able to get data, was 
higher for DNA from blood (0.82) than pellets (0.76) (Table 1.4).  
 
Genotyping error 
Average genotyping error rate calculated by repeated PCR amplification and 
allele scoring using DNA extracted from blood (n=178) and pellet (n=541) samples was 
0.16 and 0.10, respectively, for re-analyzed microsatellite loci. PCR did not produce 
usable amplicons for five microsatellite loci (IGF-1, RT1, RT5, NVHRT03, and CRFA) 
using DNA extracted from blood, and for three microsatellite loci (IGF-1, RT5, and 
CRFA) using DNA extracted from pellets. 
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Predictors of downstream genotyping success 
DNA yield and PCR amplification success of the sex-linked primer pair 
SE47/SE48 were tested in order to determine whether they could be used as predictors of 
downstream success, particularly genotyping success. Linear regression detected almost 
no ability for DNA yield to predict genotyping success using DNA extracted from blood 
(r
2
 = 0.006; p = 0.229) or pellets (r
2
 = 0.009; p = 0.127) (Fig. 1.5). DNA extracted from 
pellets that successfully PCR amplified at the sex-linked loci had higher genotyping 
success at autosomal loci compared to those that failed to amplify at this locus (Table 
1.5). The relationship between sex determination PCR and genotyping success could not 
be completed for DNA from blood or tissue samples because sex determination PCR 
success was high, resulting in insufficient sample size of failed sex determination PCR 
for comparison. 
 
Effect of pellet age 
Time since deposition was estimated for 447 samples as either <24 hours (n=178), 
24-48 hours (n=114), or >48 hours (n=155). Average DNA yield for pellet samples from 
the three age classes was not significantly different (Table 1.6). Pellets collected <24 
hours and 24-48 hours since deposition had the highest sex determination success rates 
and were not different from one another (0.85 and 0.92, respectively), whereas DNA 
from the oldest pellets had the lowest sex determination success rate (0.74) (Table 1.6). 
In addition, moose pellet samples were compared to determine whether the pellet 
age at collection influenced PCR amplification or genotyping success rates. Similar to 
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sex determination success rates, pellets collected <24 and 24-48 hours since deposition 
had the highest PCR success rates and were not different from one another (0.67 and 
0.69, respectively), whereas PCR success for pellets collected >48 hours after deposition 
was significantly lower (0.56) (Table 1.6). Genotyping success rate was the highest for 
DNA from pellets collected <24 and 24-48 hours after deposition (0.82 and 0.83, 
respectively) (Fig. 1.6). Pellets collected more than 48 hours after deposition had the 
lowest average genotyping success rate (0.69) and was significantly different from the 
two younger age classes. Similar results for PCR amplification and genotyping success 
rates were obtained when DNA extracted from pellets collected <48 hours since 
deposition was compared to DNA extracted from pellets collected >48 hours since 
deposition. 
 
Discussion 
 
DNA Yield 
DNA was successfully extracted from blood, tissue, and both sliced and whole 
pellets. Tissue samples produced both the greatest amount of DNA on average and the 
largest total volume per extraction, while pellets produced the smallest average DNA 
yield and total volume per extraction. We used one drop of blood for DNA extractions 
from Whatman FTA® cards. DNA yield for blood samples may have been higher had we 
used more than one drop of blood.  
DNA yield was not a reliable predictor of downstream genotyping success. While 
this measurement estimates the amount of DNA in a sample, it does not provide 
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information on DNA quality or the possible presence of PCR inhibitors. Samples with 
high DNA yield may actually have had some level of DNA degradation, and indeed, we 
found evidence supporting this.  
DNA extracted from blood had the highest average PCR amplification success, 
for both sex-linked and autosomal microsatellites. This suggests higher quality for DNA 
extracted from blood than tissue, as tissue samples measured greater average DNA yield. 
DNA extracted from pellets had the lowest sex determination success, supporting 
evidence for lower average DNA yield. 
 
Genotyping and PCR success 
Overall we achieved similar genotyping success for samples originating from 
blood and pellets. However, the effort required to achieve those results was much greater 
for pellet samples compared to blood samples. This was because PCR amplification 
success was lower using DNA from pellets compared to blood, a consequence of using 
lower quantity and quality DNA. Genotyping error was higher for DNA extracted from 
blood compared to DNA from pellets; however, this was likely due to the smaller sample 
size using DNA from blood compared to pellets. For regions or populations where 
noninvasive genetic sampling is the only feasible option, moose pellet samples are an 
alternative source of DNA. For other areas with access to higher quality samples, such as 
blood or tissue, we found these samples to be more efficient and preferable.  
Reported PCR amplification success using DNA from feces has been variable 
(Broquet et al. 2007; Wehausen, 2004), and is likely due to more factors than the DNA 
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source used. For example, methods of sample collection, storage, and extraction, can all 
affect DNA quality and downstream success (Wehausen, 2004; Roon et al. 2003; Waits 
& Paetkau, 2005). The effectiveness of these methods has been tested, but with no clear 
consensus (Beja-Pereira et al. 2009; Luikart et al. 2006). The lack of consensus is likely 
influenced by inherent variation among species and environmental variables (Waits & 
Paetkau, 2005), therefore it is essential to conduct a pilot study before beginning large-
scale extractions (Taberlet, et al. 1999). 
 
Improvements 
We made many attempts to improve PCR success using DNA from pellets, 
including testing multiple DNA extraction kits and protocols, adding BSA to PCR to 
remove PCR inhibitors, using the pre-amplification method for PCR, and testing a variety 
of PCR conditions (optimizing PCR master mix ingredients and thermocycler programs) 
for each microsatellite locus.  
The average amount of DNA extracted from sliced pellets was greater than that 
from whole pellets using the surface washing method. A similar comparison using whole 
pellets and sliced outer pellet material in bighorn sheep found no difference in extracted 
DNA yield (Wehausen 2004). However, the differences could be due to the sample size 
in our study being substantially larger, and differences in species, environmental 
conditions, and extraction protocols. We found slicing pellets to be a more time 
consuming process with increased probability of contamination through exposure to 
multiple laboratory surfaces (cutting surface, razor, and forceps), even though protocols 
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were in place to minimize this possibility. Additionally, accidental inclusion of inner 
pellet may increase PCR amplification failure and variation among samples (Wehausen 
2004). Therefore, although the sliced pellet method resulted in higher average DNA 
yield, we prefer the whole pellet surface washing method. 
Although not quantified, we saw noticeable improvement in PCR success using 
DNA extracted from pellets with the inclusion of BSA. BSA was not as beneficial when 
attempting to amplify DNA extracted from blood or tissue. BSA does not have a 
noticeable effect on PCR amplification success using DNA with low levels of PCR 
inhibitors (Kreader, 1996). Thus, the difference in the effect of including BSA provides 
evidence for increased levels of PCR inhibitors in DNA extracted from pellets compared 
to either blood or tissue.  
The pre-amplification method for PCR was beneficial for six microsatellites; 
however, it required more resources and number of PCRs. In some cases, it caused non-
specific amplification or amplification patterns that created difficulty for allele scoring. 
Therefore, this method should be used with caution. 
 
Recommendations 
For pellets, time since deposition affected downstream success. DNA is degraded 
by several environmental conditions (high temperature, precipitation, UV radiation, and 
microorganisms), thus the longer it is subjected to adverse conditions, the less likely the 
pellet will contain usable DNA. Therefore, selecting fresh pellets (<48 hours after 
deposition) will likely result in better quality and quantity DNA and improved PCR 
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amplification and genotyping success rates. However, samples collected in dry or 
protected areas may have a substantially larger window for collection (Brinkman et al. 
2010b). In the future, decay functions could be created using more precise estimates of 
pellet age to determine the point or age in which pellets no longer contain usable viable 
DNA. 
There is still variability in DNA quality and quantity from fresh pellets, and even 
between pellets from the same pellet pile (Taberlet et al. 1996). Poor quality samples can 
be removed from analysis based on PCR amplification success using primer pair 
SE47/SE48. Other microsatellites could also be used for this purpose; however, the 
benefit of using a sex-linked microsatellite is to confirm the sex of the individual, which 
is often missing from noninvasively collected samples.  
Avenues of future work include testing the effectiveness of sample collection and 
storage methods. Blood and tissue samples were collected and stored before our study 
began, and we used reported methods from other noninvasive genetic studies for 
collection and storage (Ebert et al. 2012; Carr et al. 2010). However, there are several 
reasons why these factors may have influenced our results. First, the tissue samples used 
may have been inherently of lower starting quality. MN moose tissue samples came from 
sick moose that were either found dead or were euthanized due to their condition. Death 
and subsequent post-mortem decomposition result in DNA degradation, particularly in 
liver tissue (Alaeddini et al. 2010). Second, although attempts were made to preserve 
DNA by storing tissue samples in -20°C freezers, these methods have not proven entirely 
effective at eliminating DNA degradation (Dawson et al. 1998). This is especially true 
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after long storage periods. Storage length beyond six months decreases both DNA yield 
and PCR amplification success for multiple DNA source types (Roon et al. 2003). Not 
only were tissue samples from potentially compromised individuals, they were stored 
substantially longer than either blood or pellet samples. Extracted DNA quantity and 
quality from tissue may have been improved using samples collected more recently or if 
DNA had been extracted immediately following collection. 
 
Concluding Remarks 
 Population genetic studies of moose have traditionally used DNA extracted from 
tissue, blood, or a combination of those two DNA sources. Similar to what has been 
found for other ungulate species (Ebert et al. 2012; Brinkman et al. 2010a; Luikart et al. 
2006) we have shown that moose fecal pellets are viable sources of DNA. However, the 
source type and methods used can significantly influence the amount of data able to be 
collected and the resources (time and money) required. 
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Table 1.1 Characteristics of 1 sex-linked and 15 autosomal microsatellites used in genetic 
analysis. 
 
Locus Primer sequences 
Annealing 
Temp (°C) 
PCR Method 
 SE47
¥
 5'-CAGCCAAACCTCCCTCTGC-3' 53 Single step 
 SE48
¥
 5'-CCCGCTTGGTCTTGTCTGTTGC-3' 
  
 NVHRT01
#‡∏
 5'-GCAGTCTTCCCCTTTCTT-3' 50 Single step 
 
 
5'-GATTGCAGAGTTGGACACTA-3' 
 
 
 RT1
‡∏ φ
 5'-TGCCTTCTTTCATCCAACAA-3' 47 Pre-amp 
 
 
5'-CATCTTCCCATCCTCTTTAC-3' 
 
 
 BM888
‡‼₺
 5'-AGGCCATATAGGAGGCAAGCTT-3' 50 Single step 
 
 
5'-CTCGGTGAGCTCAAAACGAG-3' 
 
 
 BM1225
† Ѱ₺π
 5'-TTTCTCAACAGAGGTGTCCAC-3' 50 Single step 
 
 
5'-ACCCCTATCACCATGCTCTG-3' 
 
 
 KCSN
•
 5'-ATGCACCCTTAACCTAATCCC-3' 50 Pre-amp 
 
 
5'-GCACTTTATAAGCACCACAGC-3' 
 
 
 BM2830
†∏
 5'-AATGGGCGTATAAACACAGATG-3' 50 Single step 
 
 
5'-GCATTTTTGTGTTAATTTCATGC-3' 
 
 
 BM4513
 Ѱ‡‼₺ π
 5'-GCGCAAGTTTCCTCATGC-3' 50 Single step 
 
 
5'-TCAGCAATTCAGTACATCACCC-3' 
 
 
 Cervid14
 π
 5'-TCTCTTGCGTCTCCTGCATTGAC-3' 54 Single step 
 
 
5'-AATGGCACCCACTCCAGTATTCTTC-3' 
 
 
 BM848
 Ѱ‼₺
 5'-TGGTTGGAAGGAAAACTTGG-3' 54 Single step 
 
 
5'-CCCTCTGCTCCTCAAGACAC-3' 
 
 
 RT9
 Ѱ‡‼₺φ
 5'-TGAAGTTTAATTTCCACTCT-3' 54 Single step 
 
 
5'-CAGTCACTTTCATCCCACAT-3' 
 
 
 RT24
 Ѱ‼₺∏ φ
 5'-TGTATCCATCTGGAAGATTTCAG-3' 54 Single step 
 
 
5'-CAGTTTAACCAGTCCTCTGTG-3' 
 
 
 RT30
*‡‼₺∏ φ
 5'-CACTTGGCTTTTGGACTTA-3' 54 Single step 
 
 
5'-CTGGTGTATGTATGCACACT-3' 
 
 
 Map2C
 Ѱ₺
 5'-TTTACCAGACAGTTTAGTTTTGAGC-3' 54 Single step 
 
 
5'-AAGGATTCTGTCTGATACCACTTAG-3' 
 
 
 NVHRT21
#‡∏
 5'-GCAGCGGAGAGGAACAAAAG-3' 50 Pre-amp 
 
 
5'-GGGGAGGAGCAGGGAAATC-3' 
 
 
 BL42
Ѱ‼₺
 5'-CAAGGTCAAGTCCAAATGCC-3' 49 Pre-amp 
 
 
5'-GCATTTTTGTGTTAATTTCATGC-3' 
 
 
 IGF-1
• π
 5'-GAGGGTATTGCTAGCCAGCTG-3' 54 Single step 
 
 
5'-CATATTTTTCTGCATAACTTGAACCT-3' 
 
 
 RT5
‡‼∏ φ
 5'-CAGCATAATTCTGACAAGTG-3' 54 Single step 
 
 
5'-AATTCCATGAACAGAGGAG-3' 
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NVHRT03
#
 5'-TGGAGAGCTGAGTATGAAAG-3' 54 Pre-amp 
 
 
5'-AGAAATGCAGCTACCTAAAAG-3' 
 
 
 CRFA• 5'-CTCGCTCACCTGCAGAAGCACC-3' 53 Pre-amp 
 
 
5'-GCTGAGCAGCCGTCTAAGTTGC-3' 
   
References: ‡Haanes et al. 2011; ∏Schmidt et al. 2009; ₺Murray et al. 2012; ‼Hundertmark 2009 
†Broders et al. 1999; •Cronin et al. 2001; ѰFinnegan et al. 2011; φWilson et al. 1997; πWilson et al. 2003; 
¥Brinkman and Hundertmark 2009; #Roed and Midthjell 1998. 
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Table 1.2 PCR mixtures for single step and pre-amplification methods 
 
PCR Mixture Single step 1st step pre-amp 2nd step pre-amp 
GoTaq Flexi buffer 1x 1x 1x 
MgCl2 2 mM 3 mM 2 mM 
dNTPs 0.2 mM 0.2 mM 0.2 mM 
Forward primer 0.08 µM 0.1 µM each 0.08 µM 
Reverse primer 0.8 µM 0.1 µM each 0.8 µM 
Labeled primer 0.8 µM - 0.8 µM 
BSA 0.5 ng/µL 0.25 ng/µL 0.5 ng/µL 
GoTaq DNA polymerase 0.05 µL/reaction 1 U 0.05 µL/reaction 
DNA template 1 µL/reaction 2.4 µL/reaction 1.3 µL/reaction 
Sterile water to make 13 µL to make 10 µL to make 13 µL 
Total reaction volume 13 µL 10 µL 13 µL 
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Table 1.3 Sex determination success rate using DNA extracted from blood, tissue, and 
pellet samples. Sex was determined genetically using sex-linked primer pair SE47/SE48. 
Sex determination success was significantly greater using DNA extracted from blood 
compared to DNA from tissue or pellets (Fisher’s exact test, p < 0.01); however, sex 
determination success using extracted DNA from tissue and pellets were not significantly 
different (Fisher’s exact test, p > 0.05). 
 
DNA Source 
Type 
n 
Sex determination 
success rate 
Blood 251 1.00 
Tissue 33 0.91 
Pellets 460 0.83 
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Table 1.4 PCR amplification and genotyping success rates using DNA extracted from 
blood and pellet samples. PCR amplification success rate, the proportion of PCRs that 
were successful, was greater using DNA extracted from blood than DNA extracted from 
pellets (χ2= 56.63; d.f. = 1; p < 0.001). Genotyping success rate, the proportion of 
microsatellites that we were able to get information for, was also greater using DNA 
extracted from blood than DNA extracted from pellets (t506 = 6.04, p < 0.001). Both PCR 
amplification and genotyping success rates were calculated using 15 autosomal 
microsatellite markers. 
 
    Success Rates 
DNA Source  n 
PCR 
amplification 
Genotyping 
Blood 249 0.81 0.82 
Pellets 269 0.63 0.76 
Significance   *** *** 
NS p > 0.05; * p < 0.05; ** p < 0.01; *** p < 0.001 
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Table 1.5 Average genotyping success rates for DNA extracted from moose pellets that 
successfully amplified and failed to amplify using sex-linked microsatellite (SE47/SE48). 
DNA samples that produced sex determination results had higher genotyping success 
rates than DNA that failed to amplify at this locus (t36 = -4.61, p < 0.001). 
 
Sex 
Determination 
n 
Genotyping 
Success Rate 
Successful 236 0.78 
Failed 31 0.59 
Significance - *** 
NS p > 0.05; * p < 0.05; ** p < 0.01; *** p < 0.001 
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Table 1.6 Effect of moose pellet age on DNA yield, sex-linked microsatellite PCR 
amplification success (sex-linked PCR success), and autosomal microsatellite PCR 
amplification success (autosomal PCR success) using 15 microsatellite markers using 
pellets collected >24 (n=84), 24-48 (n=65), and >48 (n=109) hours after deposition. 
Pellets in >48 hours age class ranged from 48 hours to months since deposition. Average 
DNA yield was not significantly different between different age classes (F2,255 = 1.73, p = 
0.18). Sex determination success for pellets in <24 and 24-48 age classes were not 
different (p = 0.10), but were different from pellets collected >48 hours after deposition 
(p = 0.0003). PCR success rate for pellets in <24 and 24-48 age classes were not different 
(χ2 = 1.31, d.f. = 2, p = 0.25), but were different from pellets collected >48 hours after 
deposition (χ2  > 46, d.f. = 2, p < 0.001). 
 
Time Since 
Deposition (hours) 
Average DNA 
Yield (µg) 
Sex-linked 
PCR success 
Autosomal 
PCR success 
<24 2.54 0.85 0.67 
24-48 2.45 0.92 0.69 
>48 2.08 0.74 0.56 
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Figure 1.1 Location of two study areas, Yellowstone National Park and northeastern 
Minnesota, in North America. Area shaded in gray represents estimated moose 
distribution throughout North America. 
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Figure 1.2 Location of hunter harvested (n=117), GPS collared (n=132), and sick (n=36) 
moose in Minnesota. 
Ontario 
Minnesota Wisconsin 
Manitoba 
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Figure 1.3 Location of noninvasively collected pellet samples (n=489) in the northern 
range of Yellowstone National Park. 
 
Wyoming 
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Figure 1.4 Average DNA yield extracted from multiple DNA source types. DNA sources 
were from moose in Minnesota (blood, n=251; tissue, n=31) and Yellowstone National 
Park (tissue, n=2; pellet, n=489). Pellets were extracted using two methods; using (1) 
whole pellets (n=188) and (2) outer slices of pellet (n=301). ANOVA detected 
differences in DNA yield between blood, tissue, and pellets (F3,769 = 112.71, p < 0.001). 
Values not sharing a common letter (a,b,c,d) differ significantly at p < 0.05. 
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Figure 1.5 Genotyping success rate for (A) blood and (B) pellet samples of varying DNA 
yield (µg). Linear regression did not detect a relationship between DNA yield and 
genotyping success rate using DNA from blood (β = -0.004, r2 = 0.006; p = 0.229) or 
pellets (β = -0.012, r2 = 0.008; p = 0.127). 
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Figure 1.6 Effect of pellet age at collection (<24 hrs, n=84; 24-48 hrs, n=65; >48 hrs, 
n=109) on individual genotyping success rate. Pellets in >48 hrs age class ranged from 48 
hours to months since deposition. Pellets in <24 hrs and 24-48 hrs age classes were not 
different (t136 = -0.10, p = 0.92), but were different from pellets collected >48 hrs after 
deposition (t191 = -5.29, p < 0.001). 
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Chapter 2 Prevalence of genetic polymorphisms in 
Minnesota moose associated with prion disease in other 
cervid populations 
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Introduction 
 
Prion diseases, also called transmissible spongiform encephalopathies (TSEs), are 
fatal neurodegenerative diseases in mammals. The first documented case of TSE, 
scrapies, occurred in the mid-18
th
 century in sheep (Aguzzi & Polymenidou, 2004). Since 
then, TSEs have been discovered in humans, cattle, mink, and cervids (Collinge, 2001; 
Gajdusek & Zigas, 1959; Hartsough & Burger, 1965; May, 1968; Prusiner, 1998; 
Williams & Young, 1980). Prion diseases are of concern because of their potential impact 
on human health (Belay & Schonberger, 2005), and possible economic and ecological 
consequences. Many captive animal facilities have been depopulated due to prion disease 
outbreaks (Belay et al. 2004), and prion disease outbreaks in free-ranging cervids may 
also decrease the number of individuals in the population (Gross & Miller, 2001). 
Chronic wasting disease (CWD) is the form of prion disease associated with 
cervids.  In 1967 CWD was identified in captive mule deer in Colorado (Williams & 
Young, 1980). It has since been discovered in captive and free-ranging cervid populations 
in 23 states in the U.S., and in Canada’s Alberta and Saskatchewan provinces (NWHC, 
2015). Detection of CWD may be related to surveillance effort, which has increased 
because the spread of CWD raises concerns about the possibility of transmission to 
humans (Belay et al. 2004). There is currently no cure or vaccine for CWD (Saunders et 
al. 2012) and it is highly transmissible within and among cervid species (Miller & 
Williams, 2003; Saunders et al. 2012; Sigurdson, 2008). CWD has been found in mule 
deer (Odocoileus hemionus), white-tailed deer (O. virginianus), elk (Cervus elaphus), 
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caribou (Rangifer tarandus caribou), red deer in Europe (Cervus elaphus) and moose 
(Alces alces) (Sigurdson, 2008; Williams, 2005; MNDNR, 2015a). 
TSEs can be acquired spontaneously, genetically, or through horizontal 
transmission (Moreno-Gonzalez & Soto, 2011). Horizontal transmission appears to be the 
primary mechanism responsible for CWD infection (Saunders et al. 2012). The infectious 
agent responsible for prion disease is PrP
Sc
, a misfolded isomer of the cellular protein 
(PrP
C
). Once infected, PrP
Sc
 initiates the conversion of normal PrP
C
 to PrP
Sc 
(Collinge, 
2001). There is a variable incubation period in the early stages of infection, but PrP
Sc
 is 
eventually found throughout the infected animal, with the highest concentrations found in 
the central nervous system (CNS). Amyloid prion plaques in the CNS are responsible for 
neuronal degeneration and encephalopathy, leading to eventual death.  
No individuals appear to be immune to chronic wasting disease (Williams, 2005). 
However, there appears to be certain genetic polymorphisms in the PrP gene that result 
in increased susceptibility or decreased incubation period. White-tailed deer contain 
alleles coding for Glutamine (Q) or Histidine (H) at codon 95 and Glycine (G) or Serine 
(S) at codon 96 of the PrP gene. H and S were underrepresented in CWD+ individuals, 
suggesting that 95Q and 96G individuals are more susceptible to prion disease (Johnson 
et al. 2006; O’Rourke et al. 2004). There is a similar trend for susceptibility in elk at 
codon 132 (O’Rourke et al. 1999), where CWD+ individuals were more likely to be 
homozygous for the major allele than heterozygous or homozygous for the minor allele 
(Table 2.1).  
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Genetic variation in the PrP gene also affects prion disease incubation time 
(Table 2.1). Mule deer heterozygous at codon 225 for S and Phenylalanine (F) had longer 
incubation times compared to individuals homozygous for S (Jewell et al. 2005). Other 
PrP polymorphisms have been identified, but either have not yet been tested for 
association to prion disease or results have not been reported (Wik et al. 2012; Williams, 
2005). For example, moose in Canada (Alces alces andersonii) contain a polymorphism 
at codon 36 coding for Threonine (T) or Asparagine (N), with individuals either being 
homozygous (T) or heterozygous (T/N) (Wik et al. 2012). These polymorphisms have not 
yet been tested for correlation with CWD because they have only been reported thus far 
in moose, and there have been few cases of CWD-infected moose. 
Monitoring captive and free-ranging cervids genetically could provide useful 
information for management strategies in areas at risk for CWD. Several upper Midwest 
states near Minnesota (Iowa, Michigan, North Dakota, and Wisconsin) have recently 
reported cases of CWD in free-ranging deer (IADNR, 2015; MIDNR, 2015; NDGFD, 
2015; WIDNR, 2015). Moose and other cervid species in Minnesota could be at risk of 
CWD infection if management strategies are unable to prevent its spread into the state. 
We investigated the PrP sequence in a subset of MN moose in order to (1) identify 
genetic polymorphisms in the PrP gene (2) determine if these genotypes have been 
associated with CWD in other ungulate populations, (3) identify what genotypes are 
present at specific locations known to be associated with CWD in other populations, and 
(4) determine how genetic polymorphisms are spatially distributed. 
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Methods 
 
Study area 
Minnesota 
The northern Minnesota study area transitions from prairie in the west to mixed 
conifer-deciduous forests, bog, and swamp in the east. Northwestern (NW) MN is 
relatively flat and dominated by tallgrass prairie and agriculture. Northeastern (NE) MN 
is characterized by conifer-deciduous forest, and conifer bogs and swamps. Vegetation in 
the NE consists of white pine (Pinus strobus), red pine (P. resinosa), quaking aspen 
(Populus tremuloides), paper birch (Betula papyrifera), white spruce (Picea glauca), 
balsam fir (Abies balsamea), and white cedar (Thuja occidentalis). Numerous small 
lakes, peatlands, and wet forest are also present throughout much of the NE portion of the 
state. The north-central region is a transition zone between the semi-arid prairie in the 
NW and relatively humid mixed conifer-deciduous forest in the NE. 
 
Samples 
Blood (n=61), liver tissue (n=31), and fecal pellet (n=10) samples were provided 
by the Minnesota Department of Natural Resources (MNDNR) (Fig. 2.1a). The blood 
samples are from hunter harvest (n=24), GPS collared (n=31), and sick (n=6) moose from 
2011-2013, and were stored on Whatman FTA® Classic Cards (Whatman International 
Ltd., Maidstone, UK) at room temperature. Liver tissue and pellet samples were from 
sick moose collected between 2009-2012 and 2004-2012, respectively, throughout 
northern MN, and were stored in -20°C freezers prior to DNA extraction. Samples were 
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categorized as sick or healthy based on observations by the MNDNR (Fig. 2.1b). Moose 
categorized as sick exhibited abnormal behaviors associated with neurological 
impairment, emaciation, and/or an inability to stand upright, and were either found dead 
(n=22) or were euthanized as a result of their observed condition (n=17). Date of sample 
collection, location, and estimated age of sample was provided for all samples, if known. 
Samples are males (n=53), females (n=43), and individuals of unknown sex (n=6).  
 
DNA extraction and sex determination 
Whole genomic DNA was extracted from blood, tissue, and pellet samples and 
sex was determined genetically using methods described in Chapter 1. DNA extraction 
success was determined by measuring DNA yield for each extraction and testing DNA 
amplification success of the primer pair SE47/SE48 (Brinkman & Hundertmark, 2009) 
using PCR and gel electrophoresis. 
 
Amplification and sequencing  
 
DNA from tissue and pellets was sequenced using primers 5’-GCT GAC ACC 
CTC TTT ATT TTG C-3’ and 5’-GCA AGA AAT GAG ACA CCA CCA C-3’, which 
span the prion protein gene (PrP) open reading frame (ORF). A MultiGene Optimax 
Gradient Thermal Cycler TC9610 was used for polymerase chain reaction (PCR) 
amplification with a total volume of 13 µl containing sterile water, GoTaq DNA 
polymerase and 1x GoTaq Flexi buffer (Promega Corporation, Madison, WI, USA), 2 
mM MgCl2, 0.2 mM dNTPs, 0.08 µM forward primer, 0.8 µM reverse primer, 1% bovine 
serum albumin (BSA), and 1 µl/reaction DNA. Amplification conditions included the 
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following: initial denaturation at 94°C for 2 min, followed by 10 cycles with 94°C for 30 
sec (denaturation), 64°C for 30 sec (annealing), and 72°C for 1 min (extension), with 
annealing temperature decreasing by 1°C each cycle, followed by 30 cycles with 94°C 
for 30 sec (denaturation), 54°C for 30 sec (annealing), and 72°C for 1 min (extension), 
and a final extension at 72°C for 10 min. DNA was quantified by visualizing PCR 
product on a 1% agarose gel and comparing it to Bioline Hyperladder I (Bioline, London, 
UK) using Quantity One v.4.6.6 software (Bio-Rad, Hercules, CA). DNA samples that 
failed to PCR amplify after two attempts were removed from further analysis. PCR 
products that successfully amplified were purified with ExoSAP-IT (USB Corporation, 
Cleveland, OH) using the manufacturer’s protocol, amplified a second time to 
incorporate BigDye Terminator v3.1 (Thermo Scientific, Waltham, MA), and sent to the 
University of Minnesota Biomedical Genomics Center for Sanger sequencing using an 
ABI 3730xl sequencer (Applied Biosystems, Carlsbad, CA). We used Geneious 
(Biomatters Ltd, Neward, NJ) software to analyze sequence data, and compare the quality 
of the sequence reads between DNA extracted from blood, tissue, and pellet samples. Our 
sequences were aligned to a cervid sequence from previous work imported from 
GenBank (Alces alces alces JQ290077). In MN moose, we identified observed genotypes 
at polymorphic regions in the PrP gene that have been correlated with CWD in other 
populations (Table 2.1), and identified polymorphisms at other locations.  
 
Spatial distribution and statistical analysis 
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Spatial distribution of polymorphisms in Minnesota moose was plotted in 
ArcMAP 10.1. A Fisher’s exact test for independence was used to determine whether any 
polymorphisms found in the PrP gene were significantly different between sick and 
healthy moose. 
 
Results 
 
Extraction and PCR success 
DNA quantification was successful for 100%, 84%, and 40% of the total samples 
from blood, tissue, and pellets, respectively. DNA from five tissue and six pellet samples 
were removed from further analysis due to poor PCR amplification success. Of the DNA 
samples that were sequenced, we detected no differences in sequence read quality 
between the three sample sources. An average of 90.1% (±2.2) of the bases in each 
sequence read obtained using DNA from blood, tissue, and pellet samples were high 
quality, based on base call confidence in Geneious. 
 
Polymorphisms in PrP gene 
A sequence analysis of the PrP gene from 90 free-ranging moose in Minnesota 
identified polymorphisms at codon 209. Individuals were either homozygous for 
methionine (MM) or isoleucine (II) or heterozygous (MI) (Table 8). The allele encoding 
methionine (M) was present with a frequency of 0.35, and the allele encoding isoleucine 
(I) was present with a frequency of 0.65. Genotype frequencies for MM, MI, and II were 
0.14, 0.41, and 0.44, respectively, and were not significantly different from Hardy-
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Weinberg equilibrium (χ2
2=
 
0.41; p = 0.52) (Table 2.2). Additionally, two silent 
substitutions, reported in other moose populations (Wik et al. 2012), were found at 
codons 63 and 246. 
MN comparison with polymorphic regions in other ungulate populations 
Although we did not find additional polymorphisms, we identified genotypes 
present at positions associated with CWD in other populations (Table 2.3). Minnesota 
moose were fixed for Q, G, K, and S at codons 95, 96, 132, and 225, respectively. Moose 
in MN were also fixed for T at codon 36, a polymorphism that has not yet been tested for 
association to CWD.  
PrP polymorphisms and MN moose health 
Both sick and healthy moose contained genotypes 209MM, 209MI, and 209II 
(Fig. 2.2). Both sick and healthy moose contained the genotype that has been 
experimentally infected with prion disease in moose (209MM); however, this genotype 
was found at the lowest frequency (Fig. 2.3). There was no relationship between health 
and genotype at codon 209 of the PrP gene (Fisher’s exact test; p = 0.415). 
 
Discussion 
 
A sequence analysis of the PrP ORF in Minnesota moose identified a 
polymorphism at codon 209. This polymorphism has been reported in North American 
moose in other regions (Baeten et al. 2007; Huson & Happ, 2006; Kreeger et al. 2006; 
Wik et al. 2012). Minnesota moose homozygous at codon 209 (209MM) had identical 
genotypes at the PrP ORF as deer with the highest susceptibility to CWD in other 
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populations (Johnson et al. 2006; O’Rourke et al. 2004). However, polymorphisms at 
codon 209 have not been rigorously tested for a correlation with CWD, primarily because 
most cervid species are fixed at this site.  
 Shiras moose homozygous at codon 209 (209MM) have been infected with CWD 
both naturally (Baeten et al. 2007) and experimentally (Kreeger et al. 2006). Kreeger et 
al. (2006) experimentally inoculated three moose that had identical genotypes to MN 
moose, including the polymorphism at codon 209 (MM, MI, and II). All three moose died 
within 567 days post inoculation from causes other than CWD; however, one moose 
(209MM) showed signs of TSE in lymphoid and nervous tissues. For moose, more 
information is essential for a better understanding of the relationship between genetic 
polymorphisms and CWD susceptibility.  
Moose containing the genotype associated with increased susceptibility to CWD 
appeared in NE MN, but not in NW MN. While this may be the result of small and biased 
sampling, it is worth further study for several reasons. First, this would indicate that some 
moose in northeastern Minnesota could be more susceptible to CWD. Second, certain 
polymorphisms in the PrP gene may be linked to other illnesses, as was found in 
Scandinavian moose afflicted with Moose Wasting Syndrome (MWS) (Wik et al. 2012). 
While we did not identify a relationship between health and genotype in our samples, the 
small sample size may have affected our ability to detect such a relationship. In addition, 
sick moose were categorized as such based on several physical or behavioral 
observations, which would create difficulties in identifying a relationship to a single 
cause or condition. None of the moose used in our study had CWD (Butler et al. 2013; 
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Carstensen et al. 2014). Further investigation using additional samples would produce a 
finer scale spatial distribution of polymorphisms for codon 209, and more statistical 
power to explore potential patterns. 
Minnesota is bordered by several states with CWD in free-ranging deer. The 
MNDNR is actively managing to prevent CWD from entering the state. CWD has been 
detected in three captive elk herds (two in 2002 and one in 2009), one captive white-
tailed deer herd (2006), one captive European red deer herd (2012), and a single free-
ranging white-tailed deer in 2010 (MNDNR, 2015a). The MNDNR developed a 
comprehensive CWD monitoring program for free-ranging white-tailed deer in 2002 
(MNDNR, 2015b). This program involves targeted monitoring of wild deer for the 
presence of CWD. A detailed contingency plan was also created for managing the disease 
if it is detected in captive or free-ranging cervids.  
In several areas, controlling CWD after it has been detected has proven to be 
difficult because horizontal transmission is so efficient (Miller & Williams, 2003; 
Saunders et al. 2012) and CWD is hard to identify in free-ranging individuals (Williams 
et al. 2002). Infectious prions are released into the environment through shedding from 
infected individuals (e.g. blood, saliva, and feces) or decomposing carcasses (Belay et al. 
2004; Mathiason et al. 2006; Miller et al. 2004; Miller & Williams, 2003; Saunders et al. 
2012; Tamgüney et al. 2009; Williams et al. 2002). Infectious prions have been found in 
areas years after infected animals were last found there (Miller et al. 2004). Once released 
into the environment, infectious prions persist by binding to soil particles. Prions can 
become more infectious through conformational changes that occur as a result of binding 
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with soil particles (Johnson et al. 2007). For these reasons, detection and removal of 
CWD+ individuals before the disease becomes established is critical.  
Genetic techniques such as those used here are a first step in incorporating genetic 
information into disease management strategies. We can identify individuals or groups of 
individuals with increased susceptibility to CWD or potentially other disease phenotypes, 
as a way to understand what would occur if a disease were to spread. Further, we can use 
genetic information to predict where CWD will spread, thereby providing wildlife 
managers with a more precise area to conduct disease surveillance. This approach has 
already been used to predict the spread of CWD in white-tailed deer from Wisconsin to 
Iowa (Lang & Blanchong, 2012). Microsatellite and mtDNA data provided evidence for 
efficient gene flow between the two areas, despite being separated geographically by the 
Mississippi River. CWD was detected in a hunter harvested deer in Iowa in 2013, and 
three additional cases were found the following year in 2014 (IADNR, 2015). 
Additionally, population genetic and natural history information can be used in 
combination to better understand which individuals may be more likely to facilitate 
disease persistence and spread. For example, local CWD persistence in mule deer in 
Canada is thought to be driven by female philopatry (Cullingham et al. 2011). However, 
male mule deer behavior (greater dispersal, seasonal movements during the rut, and 
certain courtship displays) may facilitate the spatial spread of CWD.  
 The Centers for Disease Control and Prevention predicts CWD will continue to 
spread into new areas (Saunders et al. 2012), highlighting the need for more research and 
continued population monitoring. We sequenced the PrP gene in moose using tissue, 
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blood, and pellets, showing that this analysis can be completed using noninvasive 
sampling techniques with low quantity and quality DNA. Because the potential for spread 
is a major concern for many wildlife diseases, the incorporation of genetic analyses using 
multiple sample types could be applicable to a wide range of diseases and study systems. 
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Table 2.1 Polymorphisms found in the prion protein gene (PrP) of cervid species and their association with chronic wasting disease 1 
(CWD). 2 
 3 
Species Codon 
Amino acid  
(major allele) 
Amino acid 
(minor allele) 
Disease phenotype (associated genotype) 
Moose
€
 36 Asparagine (N) Threonine (T) Not tested 
Moose
€
 109 Lysine (K)  Glutamine (Q) Linked to MWS in Sweden (KQ) 
Moose
#
 209 Methionine (M) Isoleucine (I) Experimentally inoculated with CWD (MM) 
Moose* 209 Methionine (M) Isoleucine (I) Natural case of CWD (MM) 
Elk
¥‡
 132 Leucine (L) Methionine (M) Increased susceptibility (MM) 
White-tailed deer
∏‼
 95 Glutamine (Q) Histidine (H) Increased susceptibility (QQ) 
White-tailed deer
∏‼
 96 Glycine (G) Serine (S) Increased susceptibility (GG) 
Caribou
φ
 225 Phenylalanine (F) Serine (S) Shorter incubation period (SS) 
Mule deer
π
 225 Phenylalanine (F) Serine (S) Shorter incubation period (SS) 
 4 
References: €Wik et al. 2012; #Kreeger et al. 2006; *Baeton et al. 2007; ¥White et al. 2010; ‡O’Rourke et al. 1999; ∏Kelly et al. 5 
2008; ‼O’Rourke et al. 2004; φHapp et al. 2007; πJewell et al. 2005.6 
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Table 2.2 Genotype and frequency of polymorphism found at PrP codon 209 in 
Minnesota moose. Genotype frequencies were not significantly different from Hardy-
Weinberg equilibrium (χ2 = 0.414, d.f. = 1, p = 0.52). 
 
Genotype n 
Genotype 
frequency 
MM 13 0.14 
MI 37 0.41 
II 40 0.45 
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Table 2.3 Polymorphisms in the PRNP sequence of five cervid species. Highlighted amino acids have been correlated with CWD 
susceptibility or shorter incubation length in other populations. 
 
    Codon    
 Species 36 95 96 109 132 209 225 
 Moose (this study) T Q G K M M/I S 
 Moose#€χ* N/T** Q G K/Q*  K** M M*  M/I** S 
 Elk¥‡ - Q G - L/M M S 
 White-tailed deer∏‼ - Q/H G/S - M M S 
 Caribouφ - Q G - M M F/S 
 Mule deerπ - Q G - M M F/S 
 
*European moose (Alces alces alces), **N. American moose (Alces alces gigas, A.a.shirasii) 
References: €Wik et al. 2012; #Kreeger et al. 2006; χHuson and Happ 2006; *Baeton et al. 2007; ¥White et al. 2010; ‡O’Rourke et al. 
1999; ∏Kelly et al. 2008; ‼O’Rourke et al. 2004; φHapp et al. 2007; πJewell et al. 2005
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Figure 2.1 Location of moose samples in Minnesota sequenced at the prion protein gene 
(PrP). A) Location of samples by DNA source type: blood (n=61), tissue (n=31), and 
pellet (n=10). B) Location of samples further categorized as healthy or sick based on 
observations by the MNDNR. All moose samples have been tested for prion disease, and 
produced negative results. 
Manitoba 
Manitoba Ontario 
Ontario 
Minnesota 
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Wisconsin 
Wisconsin 
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Figure 2.2 Distribution of polymorphic genotypes for sick (filled in circles) and healthy 
(hollow circles) moose in northern Minnesota. Moose were either homozygous for 
methionine (MM) or isoleucine (II) or heterozygous (MI). Sick moose were categorized 
as such for several observed conditions, but all tested negative for chronic wasting 
disease. 
 
Ontario Manitoba 
Minnesota Wisconsin 
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Figure 2.3 Observed genotypes for sick (n=36) and healthy (n=54) moose at codon 209 of 
the prion protein gene (PrP). Moose were either homozygous for methionine (MM) or 
isoleucine (II) or heterozygous (MI). The number of individuals with each genotype is 
represented within each corresponding bar. There was no association between health and 
genotype at this location (Fisher’s exact test, p = 0.415). 
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Supplementary Materials 
 
Moose DNA extraction protocol for FTA cards 
Fermentas/Thermo Scientific GeneJET Whole Blood Genomic 
DNA Purification Kit (#K0782) 
 
Before Starting: 
 
1. Check to make sure all stocks of chemicals and supplies are available. 
2. Turn on water bath (56°C) 
3. Prepare extraction supplies 
Ethanol and kim-wipes 
Sterilized 4 mm hand punch 
Pipette and pipette tips 
1.5 mL microcentrifuge tubes 
Fermentas/Thermo Scientific GeneJET Whole Blood Genomic DNA 
Purification Kit 
4. Label 2-1.5 mL microcentrifuge tubes (not included in kit) and 1 spin column 
(included in kit) for each sample with sample lab ID#. 
5. Use sterile 4 mm hand punch to punch out one full dried blood drop and place 
into labeled microcentrifuge tube. Replace FTA card with remaining drop back 
into sample envelope and put in ‘Done’ sample bag. Sterilize hand punch with 
ethanol between samples. 
6. Add 200 µl of 1x PBS and incubate 10 minutes at room temperature. 
7. Add 20 µl of Proteinase K Solution to 200 µl of whole blood, mix by vortexing. 
8. Add 400 µl of Lysis Solution, mix thoroughly by vortexing to obtain a uniform 
suspension. 
9. Incubate sample at 56°C for 60 minutes, vortexing samples every 10 minutes. 
10. Add 200 µl of (96-100%) ethanol and mix by pipetting. 
11. Transfer the prepared mixture to labeled spin column. Centrifuge for 1 minute at 
6,000 x g. 
12. Discard the collection tube containing the flow-through solution. Place the 
column into a new 2 mL collection tube (included in kit). 
13. Add 500 µl of Wash Buffer WB I (with ethanol added). Centrifuge for 1 minute at 
8,000 x g. Discard the flow-through and place the column back into the collection 
tube. 
14. Add 500 µl of Wash Buffer II (with ethanol added) to the column. Centrifuge for 
3 minutes at 21,000 x g. 
15. Empty the collection tube. Place the purification column back into the tube and 
re-spin the column for 1 minute at 21,000 x g. 
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16. Discard the collection tube containing the flow-through solution and transfer the 
column to second 1.5 mL labeled, sterile microcentrifuge tube (not included in 
kit). 
17. Add 100 µl of Elution Buffer to the center of the column membrane to elute 
genomic DNA. Incubate for 2 minutes at room temperature, then centrifuge for 1 
minute at 8,000 x g. 
18. Repeat previous step (add 100 µl Elution Buffer, incubate for 2 minutes, and 
centrifuge). 
19. Discard the purification column.  
20. Nanodrop the DNA sample. Record concentration and A260/A280 directly on 
sample label and in lab notebook. 
 
Before you go 
 
Enter lab IDs concentration, purity (A260/280 ratio), and other sample information into 
the extraction database. 
 
Sterilize equipment used in extraction and put away all equipment and supplies. 
 
Turn off hot bath. 
 
 
Final 1.5 mL 
microcentrifuge 
tube label 
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Moose DNA extraction protocol for tissue 
Thermo Scientific GeneJET Genomic DNA Purification Kit (#K0721) 
 
 
Before Starting: 
 
1. Check to make sure all stocks of chemicals and supplies are available. 
2. Turn on water bath (56°C) 
3. Prepare extraction supplies 
a. Forceps 
b. Razor blade 
c. Ethanol (EtOH) 
d. Cutting board 
e. 12 1.5 mL microcentirifuge tubes, labeled with sample IDs 
f. Digestion solution (from extraction kit) 
g. Proteinase K (from freezer) 
4. Using forceps and a razor blade, cut and weigh 0.02 grams of muscle tissue and 
place into corresponding 1.5 mL microcentrifuge tube. Repeat for remaining 
samples, making sure to wipe down forceps, razor blade, and cutting board with 
ethanol between samples. 
5. Write sample IDs on top of muscle tissue tubes, to indicate that they have been 
extracted. 
6. Add 180 µl Digestion solution and 20 µl Proteinase K to each sample. Vortex 
thoroughly. 
7. Incubate samples in 56°C water bath until the tissue is completely lysed and no 
particles remain (overnight). 
8. Add 20 µl RNase A (from freezer) to each tube; mix by vortexing. Incubate for 10 
minutes at room temperature. 
9. While samples are incubating, gather the remaining supplies: 
a. 12 DNA purification columns (labeled with sample ID) 
b. 12 extra collection tubes 
c. Lysis solution 
d. Wash buffer I 
e. Wash buffer II 
f. Elution buffer 
g. 12 1.5 mL microcentrifuge tubes (labeled with sample ID) 
h. 50% EtOH 
i. 50 mL waste tube 
10. Add 200 µl Lysis solution to each tube. Mix by vortexing for 15 seconds, until 
mixture is homogenous. 
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11. Add 400 µl 50% EtOH to each tube; mix by vortexing. 
12. Transfer each lysate to the corresponding DNA purification column. 
13. Centrifuge columns for 1 minute at 6,000 x g. 
14. Discard the collection tubes containing the flow-through; keep the purification 
columns. Place each DNA purification column into a new 2 mL collection tube. 
Add 500 µl Wash buffer I. 
15. Centrifuge columns for 1 minute at 8,000 x g. 
16. Discard the flow-through into the waste tube using a pipette, and place DNA 
purification column back into the collection tube. Add 500 µl Wash buffer II. 
17. Centrifuge columns for 3 minutes at 20,000 x g. 
18. Transfer the DNA purification columns to sterile, labeled 1.5 mL microcentrifuge 
tubes. Discard collection tubes with flow-through. 
19. Add 200 µl Elution buffer to each DNA purification column membrane. Incubate 
for 3 minutes at room temperature. 
20. Centrifuge for 2 minutes at 8,000 x g. 
21. Repeat elution and centrifuge steps (steps 19 and 20 above). 
22. Discard the purification columns. 
23. Use NanoDrop to determine concentration and purity of extractions. Record 
concentration and purity of each sample directly on sample label and in lab 
notebook. 
Before you go 
 
Enter lab IDs concentration, purity (A260/280 ratio), and other sample information into 
the extraction database. 
 
Sterilize equipment used in extraction and put away all equipment and supplies. 
 
Turn off hot bath. 
 
Final 1.5 mL 
microcentrifuge 
tube label 
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Moose pellet DNA extraction protocol for whole pellets 
Qiagen QIAamp DNA Stool Mini Kit (Cat. No. 51504) 
 
Before Starting: 
 
1. Check to make sure all stocks of chemicals and supplies are available 
2. Check Buffer ASL for precipitate. If necessary, incubate in hot water bath until 
precipitate is dissolved 
3. Turn on water bath (70°C) 
4. Prepare extraction supplies 
Ethanol and kim-wipes 
Sterilized forceps 
10 mL pipette and bulb 
Pipette and pipette tips 
50 mL, 1.5 mL, and 2.0 mL microcentrifuge tubes 
Large and small racks inside hood 
Qiagen QIAamp DNA Stool Mini Kit 
5. Determine how many extractions you are doing (up to 12). Select samples to 
extract and assign each sample a Lab ID (see YNP_Complete_Data.xls for correct 
Lab ID to assign. Lab IDs are unique and continuous). Record field and lab IDs in 
lab notebook. 
6. Label 1-50 ml (P00_), 1-2 ml (P00_-X), 1-1.5 ml (P00_), 1-2 ml (P00_-K), 1-spin 
column (P00_), and 1-1.5 ml tube with Lab ID, date, and initials on top/Lab ID 
and Field ID on side. 
7. Place InhibitEx tablet into tube labeled P00_-X. Do not touch tablet or set it on 
counter surface. 
8. Pipette 25 µl Proteinase K into each tube labeled P00_-K. Qiagen Proteinase K 
stored in kit. 
Pellet Extraction Procedure 
 
9. Remove selected sample from freezer and bring to hood. 
10. Record Field ID in lab book. Record initials, date, and assigned Lab ID on Field 
ID paper inside sample bag. 
11. Open pellet sample and use sterile forceps to remove one pellet and place in 
corresponding 50 mL tube.  
Note: Select “loose” pellet, not one frozen to others. If all are frozen 
together, thaw enough so pellets will come apart, but do not thaw more 
than is absolutely necessary. 
12. Re-close sample tightly and put remaining pellets back into freezer in ‘Done’ 
container. 
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13. Repeat steps 1-4 for all your pellet samples. Be sure to use sterilize instruments 
between samples with ethanol and kim-wipes. 
14. Using 10 mL pipette, add enough Buffer ASL to cover the pellet (~4-5 mL).  
15. Agitate samples for 1-2 minutes.  
16. Incubate at 70°C for 5 minutes. 
17. Pipette 1.4 mL (700 µl twice) of supernatant (liquid, not feces) to labeled 2 mL 
tube, containing InhibitEx tablet. Vortex immediately and continuously for at 
least 1 minute until the tablet is completely suspended. 
18. Centrifuge samples at 13,500 rpm (17,500 x g) for 3 minutes to pellet stool 
particles and inhibitors bound to the tablet. The layer of liquid on top of the pellet 
particles will be used in further steps. 
Note: If pellet begins mixing with supernatant between steps (i.e. this step 
and the next, re-centrifuge). 
19. Immediately after the centrifuge stops, pipette all (~650 µl) of the supernatant into 
a new labeled 1.5 mL microcentrifuge tube and discard the 2 mL tube with the 
pellet into the biohazard bag. 
20. Centrifuge the samples at 13,500 rpm (17,500 x g) for 3 minutes. 
21. Immediately after the centrifuge stops, pipet 600 µl supernatant from previous 
step into 2 mL tube containing 25 µl Proteinase K. Discard the 1.5 mL centrifuge 
tube into the biohazard bag. 
22. Add 600 µl Buffer AL and vortex for 15 seconds. 
23. Incubate samples at 70°C for 10 minutes.  
24. Centrifuge (quick spin) to pull liquid down off the top of the lids. 
25. Add 600 µl 100% ethanol and vortex for 10 seconds. The solution in the tube is 
called “lysate.” 
26. Add 600 µl lysate to the spin column (there will be some remaining lysate in tube 
– save for further steps). Centrifuge at 6,000 rpm (3,500 x g) for 1 minute. 
27. Place the spin column in a new collection tube. Pour filtrate into initial 50 ml tube 
for later disposal. Discard the used collection tube into the biohazard bag. 
28. Repeat two previous steps until all lysate is gone. 
29. Add 500 µl Buffer AW1 to the spin column. Centrifuge at 6,000 rpm (3,500 x g) 
for 1 minute. Discard the filtrate and the old collection tube as before. If there is 
liquid remaining in spin column, spin the filter again. 
30. Add 500 µl Buffer AW2 to the spin column. Centrifuge at 6,000 rpm for 1 
minute, then 13,300 rpm (17,000 x g) for 2 minutes. 
31. Transfer the spin column to a clean 1.5 mL centrifuge tube, with top cut off. (Cut 
top off directly before use, do not prepare beforehand). 
32. Add 100 µl Buffer AE directly onto the filter. Incubate at 70°C for 5 minutes. 
Centrifuge at 13,500 rpm (17,500 x g) for 1 minute to elute the DNA. 
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Note: DO NOT DISCARD THE FILTRATE (liquid in the collection tube 
– this is the DNA). 
33. Pipette the filtrate (from the collection tube – 100 µl) back onto the spin column. 
The second pass through the filter should increase yield. Incubate at 70°C for 5 
minutes. Centrifuge at 13,500 rpm (17,500 x g) for one minute to elute the DNA. 
Discard the spin column in the biohazard bag. 
Note: DO NOT DISCARD THE FILTRATE (liquid in the collection tube 
– this is the DNA). 
34. The filtrate in the 1.5 mL microcentrifuge tube is the DNA. Be sure the tube is 
correctly and completely labeled. Use NanoDrop to determine concentration and 
purity of extractions. Record concentration and purity of each sample directly on 
sample label and in lab notebook. 
35. Store extracted DNA samples in appropriate box in freezer - labeled ‘Yellowstone 
Moose DNA’. 
Before you go 
 
Enter field and lab IDs, concentration, A260/280 ratio, and other sample information into 
the extraction database before leaving. 
 
Sterilize equipment used in extraction (forceps, inside hood) and put away all equipment 
and supplies. 
 
Turn off hot bath and hood light. 
 
 
 
Final 1.5 mL 
microcentrifuge 
tube label 
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Moose pellet DNA extraction protocol for sliced pellets 
QIAamp Fast DNA Stool Kit (Cat. No. 51604) 
 
Before Starting: 
 
1. Ensure that Buffers AW1 and AW2 have been prepared according to the label 
instructions 
2. Check InhibitEx Buffer and Buffer AL for precipitate. If necessary, incubate in 
hot water bath until precipitate is dissolved 
3. Turn on water bath (70°C) 
4. Prepare extraction supplies 
Ethanol and kim-wipes 
Sterilized forceps, razor, and cutting surface 
Analytical scale and weigh paper 
Pipette and pipette tips 
50 mL, 1.5 mL, and 2.0 mL microcentrifuge tubes 
Cooler with ice 
Large and small racks inside hood 
QIAamp Fast DNA Stool Kit 
 
Pellet Extraction Procedure 
 
5. Remove sample from freezer. Remove single pellet from sample bag using forceps, 
and place on cutting surface. 
6. Slice ~0.28 g of outer material from pellet using razor. Weigh using analytical 
balance, and place slices in 50 mL centrifuge tube using forceps once desired 
sample size is acquired. Discard remaining pellet in biohazard. Place centrifuge 
tube on ice. Replace remaining, unused pellets back in freezer. 
7. Sterilize razor, forceps, and cutting surface using ethanol and kim-wipes. Repeat 
for remaining samples to be extracted. 
8. Pipet 2.8 mL InhibitEx Buffer into each 50 mL centrifuge tube. Vortex for 1 
minute until the stool sample is thoroughly homogenized. Centrifuge 50 mL tubes 
until bubbles/foam reduced. 
9. Pipet 2 mL of lysate into a labeled 2 mL microcentrifuge tube. Centrifuge sample 
at 20,000x g for 1 minute to pellet any stool debris. 
10. Pipet 20 µl proteinase K into a new, labeled 2 mL microcentrifuge tube. Pipet 200 
µl supernatant from step 9 into the 2 mL microcentrifuge tube containing 
proteinase K. 
11. Add 600 µl Buffer AL and vortex for 15 seconds. 
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12. Incubate at 70ºC for 10 minutes. Vortex for 5 seconds. Centrifuge tube briefly 
using minicentrifuge to remove drops from the inside of the tube lid. 
13. Add 600 µl ethanol (96-100%) to the lysate, and mix by vortexing. Centrifuge 
tube briefly using minicentrifuge to remove drops from the inside of the tube lid. 
14. Carefully apply 600 μl lysate from step 9 to the QIAamp spin column. Close the 
cap and centrifuge at 6,000 x g for 1 minute. Place the QIAamp spin column in a 
new 2 mL collection tube, and discard the tube containing the filtrate. 
15. Repeat step 14 until all of the lysate has been loaded on the column. 
16. Carefully open the QIAamp spin column and add 500 μl Buffer AW1. Centrifuge 
at full speed for 1 min. Place the QIAamp spin column in a new 2 mL collection 
tube, and discard the collection tube containing the filtrate. 
17. Carefully open the QIAamp spin column and add 500 μl Buffer AW2. Centrifuge 
at >20,000 x g for 3 minutes. Discard the collection tube 
containing the filtrate. 
18. Place the QIAamp spin column in a new 2 mL collection tube (not provided) and 
discard the old collection tube with the filtrate. Centrifuge at 20,000 x g for 3 
minutes. 
This step helps to eliminate the chance of possible Buffer AW2 carryover. 
19. Transfer the QIAamp spin column into a new, labeled 1.5 mL microcentrifuge 
tube (not provided) and pipet 100 μl Buffer ATE directly onto the QIAamp 
membrane. Incubate for 2 minutes at room temperature, then centrifuge at full 
speed for 1 minute to elute DNA. 
20. Pipet 100 µl of Buffer ATE back onto spin column membrane (the Buffer ATE 
that you just spun through), incubate for 2 minutes at room temperature, then 
centrifuge at full speed for 1 minute to elute DNA. 
21. The filtrate in the 1.5 mL microcentrifuge tube is the DNA. Be sure the tube is 
correctly and completely labeled. Immediately NanoDrop samples using Buffer 
ATE to blank NanoDrop. Record results in lab notebook and in extraction 
database. 
22. Store extracted DNA samples in appropriate box in freezer - labeled ‘Yellowstone 
Moose DNA’. 
 
Before you go 
 
Enter field and lab IDs, concentration, A260/280 ratio, and other sample information into 
the extraction database before leaving. 
 
Sterilize equipment used in extraction (forceps, inside hood) and put away all equipment 
and supplies. 
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Turn off hot bath and hood light. 
 
 
 
 
 
 
 
 
Final 1.5 mL 
microcentrifuge 
tube label 
